GSK3: A key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Reviews in the Neurosciences

Volumn 23, Issue 1, 2012, Pages 1-11

  Gao, Chong ^a   Hlscher, Christian ^b   Liu, Yueze ^a   Li, Lin ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

amyloid (A ); Alzheimer's disease; glucagon like peptide 1 (GLP 1); glycogen synthase kinase 3 (GSK3); neurofibrillary tangles (NFTs); type 2 diabetes mellitus (T2DM)

Indexed keywords

AMYLOID BETA PROTEIN; GENIPOSIDE; GLUCAGON LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LITHIUM; PHOSPHATIDYLINOSITOL 3 KINASE; TAU PROTEIN; TIDEGLUSIB;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; ELECTROPHYSIOLOGY; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; SIGNAL TRANSDUCTION;

EID: 84860520259     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/rns.2011.061     Document Type: Review

References (145)

1. Abbas, T., Faivre, E., and Hölscher, C. (2009). Impairment of synap-tic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 205, 265-271.
2. Adalbert, R., Gilley, J., and Coleman, M.P. (2007). A β, tau and ApoE4 in Alzheimer's disease: the axonal connection. Trends Mol. Med. 13, 135-142. (Pubitemid 46509745)
3. Akter, K., Lanza, E.A., Martin, S.A., Myronyuk, N., Rua, M., and Raffa, R.B. (2011). Diabetes and Alzheimer's disease: shared pathology and treatment? Br. J. Clin. Pharmacol. 71, 365-376.
4. Alvarez, G., Munoz-Montano, J.R., Satrustegui, J., Avila, J., Bogonez, E., and Diaz-Nido, J. (1999). Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. FEBS Lett. 453, 260-264. (Pubitemid 29326659)
5. Amar, S., Belmaker, R.H., and Agam, G. (2011). The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr. Pharm. Des. 17, 2264-2277.
6. Anderton, B.H., Betts, J., Blackstock, W.P., Brion, J.P., Chapman, S., Connell, J., Dayanandan, R., Gallo, J.M., Gibb, G., Hanger, D.P., et al. (2001). Sites of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp. 67, 73-80. (Pubitemid 33602675)
7. Avila, J. and Hernández, F. (2007). GSK3 inhibitors for Alzheimer's disease. Exp. Rev. Neurother. 7, 1527-1533.
8. Avila, J., Gómez de Barreda, E., Engel, T., Pérez, M., Martín-Maestro, P., Fuster-Matanzo, A., Goñi-Oliver, P., Lucas, J.J., and Hernández, F. (2010). Tau kinase I overexpression induces dentate gyrus degeneration. Neurodegener. Dis. 7, 13-15.
9. Birch, N.J. (1991). Lithium and the Cell: Pharmacology and Biochemistry (San Diego, CA: Academic Press).
10. Bouché, C., Serdy, S., Kahn, C.R., and Goldfine, A.B. (2004). The cellular fate of glucose and its relevance in type 2 diabetes. Endocr. Rev. 25, 807-830. (Pubitemid 39362297)
11. Brion, J.P., Anderton, B.H., Authelet, M., Dayanandan, R., Leroy, K., Lovestone, S., Octave, J.N., Pradier, L., Touchet, N., and Tremp, G. (2001). Neurofibrillary tangles and tau phosphoryla-tion. Biochem. Soc. Symp. 67, 81-88.
12. Broca, C., Quoyer, J., Costes, S., Linck, N., Varrault, A., Deffayet, P.M., Bockaert, J., Dalle, S., and Bertrand, G. (2008). beta-Arrestin 1 is required for PAC1 receptor-mediated potentiation of long-lasting ERK1/2 activation by glucose in pancreatic beta-cells. J. Biol. Chem. 284, 4332-4342.
13. Busciglio, J., Lorenzo, A., Yeh, J., and Yankner, B.A. (1995). β-Amyloid fibrils induce tau phosphorylation and loss of micro-tubule binding. Neuron 14, 879-888.
14. Caruso, A., Motolese, M., Iacovelli, L., Caraci, F., Copani, A., Nicoletti, F., Terstappen, G.C., Gaviraghi, G., and Caricasole, A. (2006). Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J. Neurochem. 98, 364-371. (Pubitemid 44133142)
15. Cedazo-Minguez, A., Popescu, B.O., Blanco-Millan, J.M., Akterin, S., Pei, J.J., Winblad, B., and Cowburn, R.F. (2003). Apolipoprotein E and β-amyloid (1-42) regulation of glycogen synthase kinase-3 β. J. Neurochem. 87, 1152-1164. (Pubitemid 37492856)
16. Chen, J., Park, C.S., and Tang, S.J. (2006). Activity-dependent syn-aptic Wnt release regulates hippocampal long term potentiation. J. Biol. Chem. 281, 11910-11916. (Pubitemid 43855453)
17. Chien, V., Aitken, J.F., Zhang, S., Buchanan, C.M., Hickey, A., Brittain, T., Cooper, G.J., and Loomes, K.M. (2010). The chap-erone proteins HSP70, HSP40/DnaJ and GRP78/BiP suppress misfolding and formation of β-sheet-containing aggregates by human amylin: a potential role for defective chaperone biology in type 2 diabetes. Biochem. J. 432, 113-121.
18. Christie, R.H., Freeman, M., and Hyman, B.T. (1996). Expression of the macrophage scavenger receptor, a multifunctional lipo-protein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am. J. Pathol. 148, 399-403. (Pubitemid 26056725)
19. Colea, A.R., Astellb, A., Greena, C., and Sutherlanda, C. (2007). Molecular connexions between dementia and diabetes. Neurosci. Biobehav. Rev. 31, 1046-1063.
20. Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hemmings, B.A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase b. Nature 378, 785-789. (Pubitemid 26004411)
21. Cselenyi, C.S., Jernigan, K.K., Tahinci, E., Thorne, C.A., Lee, L.A., and Lee, E. (2008). LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3 ′s phos-phorylation of β-catenin. Proc. Natl. Acad. Sci. USA 105, 8032-8037. (Pubitemid 351904702)
22. de la Monte, S.M. and Wands, J.R. (2005). Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis. 7, 45-61. (Pubitemid 40387184)
23. Delibegovic, M., Armstrong, C.G., Dobbie, L., Watt, P.W., Smith, A.J., and Cohen, P.T. (2003). Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein phosphatase 1 leads to increased weight gain, fat deposition, and development of insulin resistance. Diabetes 52, 596-604. (Pubitemid 36323564)
24. Dessalew, N., Patel, D.S., and Bharatam, P.V. (2007). 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3 β inhibitors. J. Mol. Graph. Model. 25, 885-895. (Pubitemid 46216123)
25. Dokken, B.B., Sloniger, J.A., and Henriksen, E.J. (2005). Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 288, DOI: 10.1152.
26. Donath, M.Y., Ehses, J.A., Maedler, K., Schumann, D.M., Ellingsgaard, H., Eppler, E., Reinecke, M. (2005). Mechanisms of β-cell death in type 2 diabetes. Diabetes 54, S108-S113. (Pubitemid 43343338)
27. Dong, W., Albers, J.J., and Vuletic, S. (2009). Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells. J. Neurosci. Rev. 87, 3176-3185.
28. Drubin, D.G. and Kirschner, M.W. (1986). Tau protein function in living cells. J. Cell Biol. 103, 2739-2746. (Pubitemid 17008019)
29. Dugo, L., Collin, M., Allen, D.A., Patel, N.S., Bauer, I., Mervaala, E.M., Louhelainen, M., Foster, S.J., Yaqoob, M.M., and Thiemermann, C. (2005). GSK-3 β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit. Care Med. 33, 1903-1912. (Pubitemid 41306508)
30. Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and Mandelkow, E. (1998). Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 143, 777-794. (Pubitemid 28512571)
31. Eldar-Finkelman, H. and Krebs, E.G. (1997). Phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 impairs insulin action. Proc. Natl. Acad. Sci. 94, 9660-9664.
32. Estall, J.L., Koehler, J.A., Yusta, B., and Drucker, D.J. (2005). The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation. J. Biol. Chem. 280, 22124-22134. (Pubitemid 40827868)
33. Fan, R., Li, X., Gu, X., Chan, J.C., and Xu, G. (2010). Exendin-4 protects pancreatic β cells from human islet amyloid polypep-tide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes. Metab. 12, 815-824.
34. Feyt, C., Kienlen-Campard, P., Leroy, K., N'Kuli, F., Courtoy, P.J., Brion, J.P., and Octave, J.N. (2005). Lithium chloride increases the production of amyloid-β peptide independently from its inhibition of glycogen synthase kinase 3. J. Biol. Chem. 280, 33220-33227. (Pubitemid 41397118)
35. Fonte, V., Kipp, D.R., Yerg, J., III, Merin, D., Forrestal, M., Wagner, E., Roberts, C.M., and Link, C.D. (2008). Suppression of in vivo β-amyloid peptide toxicity by overexpression of the HSP-16.2 small chaperone protein. J. Biol. Chem. 283, 784-791.
36. García, I., Fall, Y., and Gómez, G. (2010). QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr. Pharm. Des. 16, 2666-2675.
37. Gasparini, L. and Xu, H. (2003). Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 26, 404-406. (Pubitemid 37288973)
38. Gispen, W.H. and Biessels, G.J. (2000). Cognition roles of insulin and synaptic plasticity in diabetes mellitus. Trends Neurosci. 23, 524-529.
39. Gómez de Barreda, E., Pérez, M., Gómez Ramos, P., de Cristobal, J., Martín-Maestro, P., Morán, A., Dawson, H.N., Vitek, M.P., Lucas, J.J., Hernández, F., et al. (2010). Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol. Dis. 37, 622-629.
40. Gonzalez, G.A. and Montminy, M.R. (1989). Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59, 675-680. (Pubitemid 19282874)
41. Goodwin, F.K. and Jamison, K.R. (1990). Manic-Depressive Illness (New York: Oxford University Press).
42. Hanashiro, I. and Roach, P.J. (2002). Mutations of muscle glycogen synthase that disable activation by glucose 6-phosphate. Arch. Biochem. Biophys. 397, 286-292. (Pubitemid 34852293)
43. Hardy, J. (2006). A hundred years of Alzheimer's disease research. Neuron 52, 3-13. (Pubitemid 44472602)
44. Hanger, D.P., Anderton, B.H., and Noble, W. (2009). Tau phosphory-lation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119.
45. Henriksen, E.J. and Dokken, B.B. (2006). Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr. Drug Targets 7, 1435-1441. (Pubitemid 44718303)
46. Henriques, A.G., Vieira, S.I., da Cruz e Silva, E.F., and da Cruz e Silva, O.A. (2009). αβ hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures. J. Mol. Neurosci. 38, 248-255
47. Hernández, F., Nido, J.D., Avila, J., and Villanueva, N. (2009a). GSK3 inhibitors and disease. Mini Rev. Med. Chem. 9, 1024-1029.
48. Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Goñi-Oliver, P., Lucas, J.J., and Avila, J. (2009b). The role of GSK3 in Alzheimer disease. Brain Res. Bull. 80, 248-250.
49. Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J.J., and Avila, J. (2010a). GSK3: a possible link between B amyloid peptide and tau protein. Exp. Neurol. 223, 322-325
50. Hernández, F., Langa, E., Cuadros, R., Avila, J., and Villanueva, N. (2010b) Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol. Cell. Biochem. 344, 211-215
51. Hölscher, C. (2010). The role of GLP-1 in neuronal activity and neu-rodegeneration. Vitam. Horm. 84, 331-354
52. Hölscher, C. (2011). Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem. Soc. Trans. 39, 891-897.
53. Hooper, C., Killick, R., Fernandes, C., Sugden, D., and Lovestone, S. (2011). Transcriptomic profiles of Wnt3a and insulin in primary cultured rat cortical neurones. J. Neurochem. 118, 512-520.
54. Hu, S., Begum, A.N., Jones, M.R., Oh, M.S., Beech, W.K., Beech, B.H., Yang, F., Chen, P., Ubeda, O.J., Kim, P.C., et al. (2009). GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol. Dis. 33, 93-206.
55. Huang, C.Y., Hsiao, J.K., Lu, Y.Z., Lee, T.C., and Yu, L.C. (2011). Anti-apoptotic PI3K/Akt signaling by sodium/glucose transporter 1 reduces epithelial barrier damage and bacterial translocation in intestinal ischemia. Lab. Invest. 91, 294-309.
56. Imahori, K. and Uchida, T. (1997). Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. (Tokyo) 121, 179-188. (Pubitemid 27096190)
57. Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T., and Imahori, K. (1993). Glycogen synthase kinase 3 β is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 325, 167-172. (Pubitemid 23186470)
58. Jackson, G.R., Wiedau-Pazos, M., Sang, T.K., Wagle, N., Brown, C.A., Massachi, S., and Geschwind, D.H. (2002). Human wild-type tau interacts with wingless pathway components and produces neuro-fibrillary pathology in Drosophila. Neuron 34, 509-519. (Pubitemid 34628749)
59. Jolivalt, C.G., Lee, C.A., Beiswenger, K.K., Smith, J.L., Orlov, M., Torrance, M.A., and Masliah, E. (2008). Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 86, 3265-3274.
60. Jolivalt, C.G., Hurford, R., Lee, C.A., Dumaop, W., Rockenstein, E., and Masliah, E. (2010). Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp. Neurol. 223, 422-431.
61. Jope, R.S., Yuskaitis, C.J., and Beurel, E. (2007). Glycogen syn-thase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32, 577-595. (Pubitemid 46481289)
62. Joshi, S.N. and Crutcher, K.A. (1998). Rat microglia exhibit increased density on Alzheimer's plaques in vitro. Exp. Neurol. 149, 42-50. (Pubitemid 28091013)
63. Kickstein, E., Krauss, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., Williamson, R., Fuchs, M., Köhler, A., Glossmann, H., et al. (2010). Biguanide metformin acts on tau phosphoryla-tion via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Acad. Natl. Sci. USA 107, 21830-21835.
64. Kimura, Y., Okuda, H., and Arichi, S. (1982). Effects of geniposide isolated from Gardenia jasminoides on metabolic alterations in high sugar diet-fed rats. Chem. Pharm. Bull. 30, 4444-4447. (Pubitemid 13185653)
65. Klein, P.S. and Melton, D.A. (1996). A molecular mechanism for the effect of lithium on development. Proc. Acad. Natl. Sci. USA 93, 8455-8459. (Pubitemid 26269579)
66. Kroner, Z. (2009). The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern. Med. Rev. 14, 373-379.
67. Lebel, M., Patenaude, C., Allyson, J., Massicotte, G., and Cyr, M. (2009). Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways. Neuropharmacology 57, 392-402.
68. Lee, J. and Kim, M.S. (2007). The role of GSK3 in glucose homeota-sis and the development of insulin resistance. Diabetes Res. Clin. Pract. 77, 49-57.
69. Lee, H.K., Kumar, P., Fu, Q., Rosen, K.M., and Querfurth, H.W. (2009). The insulin/Akt signaling pathway is targeted by intrac-ellular β-amyloid. Mol. Biol. Cell 20, 1533-1544.
70. Lee, Y.J., Han, S.B., Nam, S.Y., Oh, K.W., and Hong, J.T. (2010). Inflammation and Alzheimer disease. Arch. Pharm. Res. 33, 1539-1596.
71. Li, L. and Hölscher, C. (2007). Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 56, 384-402. (Pubitemid 350166529)
72. Li, Z.G., Zhang, W., and Sima, A.A. (2007). Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56, 1817-1824. (Pubitemid 47025451)
73. Li, Y., Duffy, K.B., Ottinger, M.A., Ray, B., Bailey, J.A., Holloway, H.W., Tweedie, D., Perry, T., Mattson, M.P., Kapogiannis, D., et al. (2010). GLP-1 receptor stimulation reduces amyloid-β pep-tide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 19, 1205-1219.
74. Lim, Y.A., Rhein, V., Baysang, G., Meier, F., Poljak, A., Raftery, M.J., Guilhaus, M., Ittner, L.M., Eckert, A., and Götz, J. (2010). A β and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 10, 1621-1633.
75. Liu, S.J., Zhang, A.H., Li, H.L., Wang, Q., Deng, H.M., Netzer, W.J., Xu, H., and Wang, J.Z. (2008). Overactivation of glyco-gen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. Neurochem. 87, 1333-1344. (Pubitemid 38020568)
76. Liu, J.H., Yin, F., Guo, L.X., Deng, X.H., and Hu, Y.H. (2009a) Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol. Sin. 30, 159-165.
77. Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C.X. (2009b). Brain glucose transporters, O-GlcNAcylation and phosphoryla-tion of tau in diabetes and Alzheimer's disease. J. Neurochem. 111, 242-249.
78. Lizcano, J.M. and Alessi, D.R. (2002). The insulin signalling pathway. Curr. Biol. 12, R236-R238; DOI: 10.1016/S0960-9822(02)00777-7. (Pubitemid 34271354)
79. MacAulay, K., Doble, B.W., Patel, S., Hansotia, T., Sinclair, E.M., Drucker, D.J., Nagy, A., and Woodgett, J.R. (2007). Glycogen synthase kinase 3 α-specific regulation of murine hepatic glyco-gen metabolism. Cell Metab. 6, 329-337. (Pubitemid 47450185)
80. Magdesian, M.H., Carvalho, M.M., Mendes, F.A., Saraiva, L.M., Juliano, M.A., Juliano, L., Garcia-Abreu, J., and Ferreira, S.T. (2008). Amyloid-β binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/β-catenin signaling. J. Biol. Chem. 283, 9359-9368.
81. Martin, M., Rehani, K., Jope, R.S., and Michalek, S.M. (2005). Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777-784. (Pubitemid 43090463)
82. Martinez, A. and Perez, D.I. (2008). GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J. Alzheimers Dis. 15, 181-191.
83. McClean, P.L., Parthsarathy, V., Faivre, E., and Hölscher, C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594.
84. McGeer, P.L. and McGeer, E.G. (1996). Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann. NY Acad. Sci. 777, 213-220. (Pubitemid 26149190)
85. Meares, G.P., Mines, M.A., Beurel, E., Eom, T.Y., Song, L., Zmijewska, A.A., and Jope, R.S. (2011). Glycogen synthase kinse-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells. Exp. Cell Res. 317, 1621-1628.
86. Mendes, C.T., Mury, F.B., de SáMoreira, E., Alberto, F.L., Forlenza, O.V., Dias-Neto, E., and Gattaz, W.F. (2009). Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease. Eur. Arch. Psychiatry Clin. Neurosci. 259, 16-22.
87. Meske, V., Albert, F., and Ohm, T.G. (2008). Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A-and glycogen synthase kinase-3-dependent phosphorylation of Tau. J. Biol. Chem. 283, 100-109.
88. Miyasita, S. (1976). A historical study of Chinese drugs for the treatment of jaundice. Am. J. Chin. Med. 4, 239-243.
89. Morfini, G., Szebenyi, G., Elluru, R., Ratner, N., and Brady, S.T. (2002). Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 21, 281-293. (Pubitemid 34137290)
90. Morimoto, R.I. and Gabriella Santoro, M. (1998). Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nat. Biotechnol. 16, 833-838. (Pubitemid 28405852)
91. Naslund, J., Thyberg, J., Tjernberg, L.O., Wernstedt, C., Karlstrom, A.R., Bogdanovic, N., Gandy, S.E., Lannfelt, L., Terenius, L., and Nordstedt, C. (1995). Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 15, 219-228.
92. Nielsen, J.N. and Wojtaszewski, J.F. (2004). Regulation of glycogen synthase activity and phosphorylation by exercise. Proc. Nutr. Soc. 63, 233-237. (Pubitemid 38787471)
93. Nikoulina, S.E., Ciaraldi, T.P., Mudaliar, S., Mohideen, P., Carter, L., and Henry, R.R. (2000). Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49, 263-271. (Pubitemid 30071005)
94. O'Brien, W.T. and Klein, P.S. (2009). Validating GSK3 as an in vivo target of lithium action. Biochem. Soc. Trans. 37, 1133-1138.
95. Ohtani, M., Nagai, S., Kondo, S., Mizuno, S., Nakamura, K., Tanabe, M., Takeuchi, T., Matsuda, S., and Koyasu, S. (2008). Mammalian target of rapamycin and glycogen synthase kinase-3 differentially regulate lipopolysaccharide- induced interleukin-12 production in dendritic cells. Blood 11 2, 635-643.
96. Pei, J.J., Tanaka, T., Tung, Y.C., Braak, E., Iqbal, K., and Grundke-Iqbal, I. (1997). Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56, 70-78. (Pubitemid 127470328)
97. Peineau, S., Taghibiglou, C., Bradley, C., Wong, T.P., Liu, L., Lu, J., Lo, E., Wu, D., Saule, E., Bouschet, T., et al. (2007). LTP inhibits LTD in the hippocampus via regulation of GSK3 β. Neuron 53, 703-717. (Pubitemid 46283369)
98. Pekary, A.E., Stevens, S.A., Blood, J.D., and Sattin, A. (2010). Rapid modulation of TRH and TRH-like peptide release in rat brain, pancreas, and testis by a GSK-3 β inhibitor. Peptides 31, 1803-1893.
99. Perez, M., Hernandez, F., Gomez-Ramos, A., Smith, M., Perry, G., and Avila, J. (2002). Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur. J. Biochem. 269, 1484-1489. (Pubitemid 34227089)
100. Phiel, C.J., Wilson, C.A., Lee, V.M., and Klein, P.S. (2003). GSK-3 α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435-439. (Pubitemid 36626994)
101. Porter, D.W., Kerr, B.D., Flatt, P.R., Holscher, C., and Gault, V.A. (2010). Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes. Metab. 12, 891-899.
102. Post, R.M., Weiss, S.R.B., and Chuang, D.M. (1992). Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J. Clin. Psychopharmacol. 12, 23-35.
103. Proctor, C.J. and Gray, D.A. (2010). GSK3 and p53-is there a link in Alzheimer's disease? Mol. Neurodegener. 26, 5-7.
104. Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P., and Ferreira, A. (2002). Tau is essential to β-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 99, 6364-6369.
105. Rayasam, G.V., Tulasi, V.K., Sodhi, R., Davis, J.A., and Rav, A. (2009). Glycogen kinase synthase 3: more than a namesaske. Br. J. Pharmacol. 165, 855-898.
106. Riadh, N., Allagui, M.S., Bourogaa, E., Vincent, C., Croute, F., and Elfeki, A. (2011). Neuroprotective and neurotrophic effects of long term lithium treatment in mouse brain. Biometals 24, 747-757.
107. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.Q., and Mucke, L. (2007). Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754. (Pubitemid 46717684)
108. Rodionova, E., Conzelmann, M., Maraskovsky, E., Hess, M., Kirsch, M., Giese, T., Ho, A.D., Zoller, M., Dreger, P., and Luft, T. (2007). GSK-3 mediates differentiation and activation of proin-flammatory dendritic cells. Blood 109, 1584-1592. (Pubitemid 46239592)
109. Saltiel, A.R. and Kahn, C.R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806. (Pubitemid 34000783)
110. Sanna, P.P., Cammalleri, M., Berton, F., Simpson, C., Lutjens, R., Bloom, F.E., and Francesconi, W. (2002). Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region. J. Neurosci. 22, 3359-3365. (Pubitemid 37465741)
111. Schuber, M., Gautam, D., Surjo, D., Ucki, K., Baudler, S., Schubert, D. (2004). Role for neuronal insulin resistance in neurodegenera-tive disease. Proc. Natl. Acad. Sci. USA 101, 3100-3103.
112. Semiz, S. and McNeill, J.H. (2002). Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin stimulated protein phosphatase-1 activity. Mol. Cell. Biochem. 236, 123-131. (Pubitemid 34846141)
113. Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M.B., Gich, I., Agulló, J.M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009). A novel GSK-3 β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35, 359-367.
114. Sittler, A., Lurz, R., Lueder, G., Priller, J., Lehrach, H., Hayer-Hartl, M.K., Hartl, F.U., and Wanker, E.E. (2001). Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10, 1307-1315. (Pubitemid 32600484)
115. Small, S.A. and Duff, K. (2008). Linking A β and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60, 534-542.
116. Solano, D.C., Sironi, M., Bonfini, C., Solerte, S.B., Govoni, S., and Racchi, M. (2000). Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J. 14, 1015-1022. (Pubitemid 30241680)
117. Stambolic, V., Woodgett, J.R. (1994). Mitogen inactivation of glyco-gen synthase kinase-3b in intact cells via serine 9 phosphoryla-tion. Biochem. J. 303, 701-704. (Pubitemid 24325998)
118. Stalder, M., Phinney, A., Probst, A., Sommer, B., Staufenbiel, M., and Jucker, M. (1999). Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 154, 1673-1684. (Pubitemid 29262849)
119. Stein, J., Milewski, W.M., Hara, M., Steiner, D.F., and Dey, A. (2011). GSK-3 inactivation or depletion promotes β-cell replication via downregulation of the CDK inhibitor, p27. Islets 3, 21-34.
120. Sun, X., Sato, S., Murayama, O., Murayama, M., Park, J.-M., Yamaguchi, H., and Takashima, A. (2002). Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321, 61-64. (Pubitemid 34185499)
121. Townsend, M., Mehta, T., and Selkoe, D.J. (2007). Soluble A β inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282, 33305-33312. (Pubitemid 350159548)
122. Troussard, A.A., Tan, C., Yoganathan, T.N., and Dedhar, S. (1999). Cell extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase-and glycogen synthase kinase 3-dependent manner. Mol. Cell. Biol. 19, 7420-7427. (Pubitemid 29493405)
123. Turenne, G.A. and Price, B.D. (2001). Glycogen synthase kinase 3 β phosphorylates serine 33 of p53 and activates p53's transcrip-tional activity. BMC Cell Biol. DOI: 10.1186/1471-2121-2-12. (Pubitemid 38597713)
124. Turturici, G., Sconzo, G., and Geraci, F. (2011). Hsp70 and its molecular role in nervous system diseases. Biochem. Res. Int. DOI: 618127.
125. Van Wauwe, J. and Haefner, B. (2003). Glycogen synthase kinase-3 as drug target: from wallflower to center of attention. Drug News Perspect. 16, 557-565. (Pubitemid 38094735)
126. Vehmas, A.K., Kawas, C.H., Stewart, W.F., and Troncoso, J.C. (2003). Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol. Aging 24, 321-331. (Pubitemid 36005412)
127. Voellmy, R. (2004). On mechanisms that control heat shock transcription factor activity in metazoan cells. Cell Stress Chaperones 9, 122-133. (Pubitemid 39013809)
128. Wada, A. (2009). GSK-3 inhibitors and insulin receptor signaling in health, disease, and theraputics. Front. Biosci. 14, 1558-1570.
129. Wang, X.H., Li, L., Hölscher, C., Pan, Y.F., Chen, X.R., and Qi, J.S. (2010). Val8-glucagon-like peptide-1 protects against A β1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170, 1239-1248.
130. Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., and Kirschner, M.W. (1975). A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA 72, 1858-1862.
131. Welsh, G.I. and Proud, C.G. (1993). Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem. J. 294, 625-629. (Pubitemid 23286543)
132. Whittle, B.J., Varga, C., Posa, A., Molnar, A., Collin, M., and Thiemermann, C. (2006). Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3 β. Br. J. Pharmacol. 147, 575-582. (Pubitemid 43355056)
133. Wisniewski, T. and Frangione, B. (1992). Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135, 235-238.
134. Woodgett, J.R. (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor α. EMBO J. 9, 2431-2438.
135. Woodgett, J.R. (1991). cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol. 200, 564-577.
136. Woodgett, J.R. (2003). Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr. Durg Targets Immune Endocr. Metabol. Disord. 3, 281-290.
137. Woodgett, J.R. and Cohen, P. (1984). Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim. Biophys. Acta 788, 339-347. (Pubitemid 14031544)
138. Woodgett, J.R. and Ohashi, P.S. (2005). GSK3: an in-Toll-erant protein kinase? Nat. Immunol. 6, 751-752. (Pubitemid 43090457)
139. Yamaguchi, H., Ishiguro, K., Uchida, T., Takashima, A., Lemere, C.A., and Imahori, K. (1996). Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 β and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. (Berl.) 92, 232-241. (Pubitemid 26278953)
140. Yong, Y., Ding, H., Fan, Z., Luo, J., and Ke, Z.J. (2011). Lithium fails to protect dopaminergic neurons in the 6-OHDA model of Parkinson's disease. Neurochem. Res. 36, 367-374.
141. Young, W. (2009). Review of lithium effects on brain and blood. Cell Transplant. 18, 951-975.
142. Zhao, W.Q. and Townsed, M. (2009). Insulin resistance and amyloido-genesis as a common molecular foundation for type 2 diabetes and Alzheimer disease. Biochim. Biophys. Acta 1729, 482-496.
143. Zhao, L., Teter, B., Morihara, T., Lim, G.P., Ambegaokar, S.S., Ubeda, O.J., Frautschy, S.A., and Cole, G.M. (2004). Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J. Neurosci. 8, 11120-11126. (Pubitemid 40012971)
144. Zhuo, J.M., Portugal, G.S., Kruger, W.D., Wang, H., Gould, T.J., and Pratico, D. (2010). Diet-induced hyperhomocysteinemia increases amyloid-β formation and deposition in a mouse model of Alzheimer's disease. Curr. Alzheimer Res. 2010, 140-149.
145. Zhuo, J.M., Wang, H., and Pratic ò, D. (2011). Is hyperhomocysteine-mia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol. Sci. 32, 562-571.